The IL-33/ST2 pathway — A new therapeutic target in cardiovascular disease

Miller, A. M. and Liew, F. Y. (2011) The IL-33/ST2 pathway — A new therapeutic target in cardiovascular disease. Pharmacology and Therapeutics, 131(2), pp. 179-186. (doi: 10.1016/j.pharmthera.2011.02.005)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1016/j.pharmthera.2011.02.005

Abstract

Numerous pro-inflammatory cytokines have been implicated in the pathogenesis of several cardiovascular diseases. Interleukin (IL)-33 is a new member of the IL-1 family of cytokines that promotes Th2 type immune responses by signaling through the ST2L and IL-1RAcP dimeric receptor complex. Furthermore, the biological effects of IL-33 are limited by a soluble decoy form of ST2 (sST2). Recent studies indicate a protective role for IL-33 and ST2L in atherosclerosis, obesity and cardiac remodeling. The present review summarizes currently available data showing the role for IL-33 and its receptor ST2L within cardiovascular disease, and the potential use of sST2 as a predictive cardiovascular biomarker.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Liew, Prof Foo and Miller, Dr Ashley
Authors: Miller, A. M., and Liew, F. Y.
Subjects:R Medicine > RC Internal medicine
R Medicine > RM Therapeutics. Pharmacology
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Pharmacology and Therapeutics
Journal Abbr.:Pharmacol. Ther.
Publisher:Elsevier
ISSN:0163-7258
ISSN (Online):1879-016X
Published Online:26 February 2011
Related URLs:

University Staff: Request a correction | Enlighten Editors: Update this record